文献速递消化道肿瘤与早癌消化内镜

粪便免疫化学检测在预测疑似结直肠癌症状患者病理方面优于症状:一项诊断准确性研究

Faecal immunochemical test is superior to symptoms in predicting pathology in patients with suspected colorectal cancer symptoms referred on a 2WW pathway: a diagnostic accuracy study.
PubMed 文献 · Gut · 2020-10-21

这项多中心双盲诊断准确性研究纳入9822例因疑似结直肠癌症状按2周等待转诊标准转诊并接受结肠镜检查的患者,评估粪便免疫化学检测(FIT)对结直肠癌的筛查价值。结果显示FIT在2 µg/g阈值下敏感性达97.0%,阴性结果可有效排除结直肠癌,阳性结果较症状更能筛选需紧急检查的患者。

要点

  • FIT在2 µg/g阈值下对结直肠癌敏感性为97.0%,阴性预测值99.8%。
  • FIT阳性预测值随阈值升高而增加,2、10、150 µg/g分别为8.7%、16.1%、31.1%。
  • FIT阴性结果在2 µg/g阈值下可有效排除结直肠癌,阳性结果优于症状用于筛选紧急检查。

核心结论

  • FIT在最低阈值(2 µg/g)下敏感性最大化至97.0%,阴性结果可有效排除结直肠癌,阳性结果优于症状用于筛选需紧急检查的患者。

研究设计与样本

  • 多中心、双盲诊断准确性研究,2017年10月至2019年12月在英格兰50家国家卫生服务体系(NHS)医院开展。
  • 纳入因疑似结直肠癌症状符合NHS England 2周等待紧急转诊标准并分诊至结肠镜检查的患者,邀请其进行定量FIT。
  • 最终分析纳入9822例患者,评估FIT对结直肠癌的敏感性及相关变量对诊断准确性的影响。

主要发现

  • 结肠镜检查时结直肠癌患病率为3.3%。
  • FIT阳性率在2、10、150 µg血红蛋白/g粪便(µg/g)阈值下分别为37.2%、19.0%、7.6%。
  • FIT对结直肠癌的阳性预测值在2、10、150 µg/g阈值下分别为8.7%(95% CI 7.8%至9.7%)、16.1%(95% CI 14.4%至17.8%)、31.1%(95% CI 27.8%至34.6%)。
  • FIT对结直肠癌的阴性预测值在2、10、150 µg/g阈值下分别为99.8%(95% CI 99.7%至99.9%)、99.6%(95% CI 99.5%至99.7%)、98.9%(95% CI 98.7%至99.1%)。
  • FIT对结直肠癌的敏感性在2、10、150 µg/g阈值下分别为97.0%(95% CI 94.5%至98.5%)、90.9%(95% CI 87.2%至93.8%)、70.8%(95% CI 65.6%至75.7%),特异性分别为64.9%(95% CI 63.9%至65.8%)、83.5%(95% CI 82.8%至84.3%)、94.6%(95% CI 94.1%至95.0%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess whether a faecal immunochemical test (FIT) could be used to select patients with suspected colorectal cancer (CRC) symptoms for urgent investigation. DESIGN: Multicentre, double-blinded diagnostic accuracy study in 50 National Health Service (NHS) hospitals across England between October 2017 and December 2019. Patients referred to secondary care with suspected CRC symptoms meeting NHS England criteria for urgent 2 weeks wait referral and triaged to investigation with colonoscopy were invited to perform a quantitative FIT. The sensitivity of FIT for CRC, and effect of relevant variables on its diagnostic accuracy was assessed. RESULTS: 9822 patients were included in the final analysis. The prevalence of CRC at colonoscopy was 3.3%. The FIT positivity decreased from 37.2% to 19.0% and 7.6%, respectively, at cut-offs of 2, 10 and 150 µg haemoglobin/g faeces (µg/g). The positive predictive values of FIT for CRC at these cut-offs were 8.7% (95% CI, 7.8% to 9.7%), 16.1% (95% CI 14.4% to 17.8%) and 31.1% (95% CI 27.8% to 34.6%), respectively, and the negative predictive values were 99.8% (95% CI 99.7% to 99.9%), 99.6% (95% CI 99.5% to 99.7%) and 98.9% (95% CI 98.7% to 99.1%), respectively. The sensitivity of FIT for CRC decreased at the same cut-offs from 97.0% (95% CI 94.5% to 98.5%) to 90.9% (95% CI 87.2% to 93.8%) and 70.8% (95% CI 65.6% to 75.7%), respectively, while the specificity increased from 64.9% (95% CI 63.9% to 65.8%) to 83.5% (95% CI 82.8% to 84.3%) and 94.6% (95% CI 94.1% to 95.0%), respectively. The area under the receiver operating characteristic curve was 0.93 (95% CI 0.92 to 0.95). CONCLUSION: FIT sensitivity is maximised to 97.0% at the lowest cut-off (2 µg/g); a negative FIT result at this cut-off can effectively rule out CRC and a positive FIT result is better than symptoms to select patients for urgent investigations. TRIAL REGISTRATION NUMBER: ISRCTN49676259.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. D'Souza N, Georgiou Delisle T, Chen M, et al. Faecal immunochemical test is superior to symptoms in predicting pathology in patients with suspected colorectal cancer symptoms referred on a 2WW pathway: a diagnostic accuracy study. Gut. 2020. PMID: 33087488. doi:10.1136/gutjnl-2020-321956

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。